The FDA has given the green light to the first major new classes of antidepressant therapies in decades, opening up new avenues for therapeutic development.
As medical marijuana businesses set up shop across the U.S., a handful of companies are taking the pharmaceutical route, guiding cannabis-derived drugs through clinical trials.
Dozens of intranasally delivered vaccines targeting SARS-CoV-2 are in development. Could they pave the way for widespread nasal vaccination in the future?